The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | From bb2121 to bb21217: does bb007 improve efficacy in MM?
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the CRB-402 study (NCT03274219) of bb21217, a next-generation anti-BCMA CAR T-cell therapy based on idecabtagene vicleucel (bb2121), that uses the same lentiviral CAR-T design, but adds the P3K inhibitor bb007 during ex vivo culture to enrich the drug product for memory-like T-cells, in order to increase persistence. Initial efficacy results with bb21217 CAR-T therapy in heavily pretreated relapsed/refractory multiple myeloma (MM) are encouraging. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
